In April this year, a study was published in the Journal of Pediatric Gastroenterology and Nutrition, which further confirmed that children infected with hepatitis B virus are not necessarily in an immune tolerance period, that is, the body and hepatitis B virus maintain “peaceful coexistence.” in this way.
Talking about the urgency of new drugs for hepatitis B, children can see hepatitis and fibrosis, targeting the entire viral replication cycle
This trial was jointly completed by 12 medical researchers in this field. The subject was liver histology in the United States and Canada to treat chronic hepatitis B in infants. The main purpose of the study is to understand that chronic hepatitis B virus infection is the main cause of its morbidity and mortality. The study conducted liver histology examinations in children with chronic hepatitis B virus infection in the United States and Canada. A total of 134 participants were involved in the study. The subjects were simple fibrosis histology scores, liver biopsies, and other laboratory correlation analyses for children with chronic hepatitis B infection.
It was found that 51% of the 134 cases were male, 60% were patients with vertically transmitted infections, and 69% of liver biopsies were chronic hepatitis B with positive e antigen. In addition, their HBV-DNA was generally high, and the average level of serum alanine aminotransferase was also very high. 38% of the subjects had mild portal vein inflammation, and 62% of the subjects had mild portal vein inflammation. 18% had no fibrosis, 59% found portal vein dilation without bridging fibrosis, 19% had bridging fibrosis, and 4% had cirrhosis.
In the standard of antiviral treatment, the level of alanine aminotransferase that is more concerned in liver disease clinicians or new drug development trials is also the focus of this research. Studies have noted that changes in alanine aminotransferase have a significant positive correlation with liver inflammation and liver fibrosis. In the antiviral standards mentioned in the “Guidelines for the Prevention and Treatment of Chronic Hepatitis B”, the duration of infection, age, and HBV-DNA levels are not directly related to liver fibrosis.
Fibrosis-4 is not related to the degree of liver fibrosis in the subjects, but it is related to liver inflammation. Aspartate aminotransferase / platelet ratio index is related to liver inflammation and liver fibrosis. Therefore, a study of 134 children with chronic hepatitis B infection in the United States and Canada concluded that hepatitis B infection may lead to significant liver inflammation and hepatic fibrosis in children, reflecting the key indicators of liver inflammation and fibrosis, and remains the guide Mentioned serum alanine aminotransferase.
Xiaofan Health is based on this study published in the Foreign Medical Journal of Pediatric Gastroenterology and Nutrition in April this year. Overall, the 2019 version of the “Chronic Hepatitis B Prevention and Treatment Guidelines” is appropriate to expand the indications. The main reason is that children are chronically infected. Hepatitis B virus may also cause obvious inflammation of the liver, and even a certain degree of fibrosis. In our country, there are two main types of viral hepatitis, hepatitis B and C.
Xiaofan Health Conclusion: The development of innovative drugs for hepatitis B has become an urgent global demand. Not only the children with chronic hepatitis B indicated in the above study also have liver inflammation and fibrosis, but the aging of hepatitis B should also attract attention from all walks of life in the society Conduct research and development of innovative drugs for hepatitis B. Hepatitis B virus enters the human body through multiple steps, and most antiviral drugs are currently targeted at these different steps.
After entering the human body, the virus enters the liver cells by attaching to the liver cells, and then is released from the liver cells into the blood. The cccDNA of hepatitis B virus template is a medical difficulty. CccDNA mainly exists in the liver cell nucleus. As the initial replication template of the virus, most antiviral drugs cannot work on it. The new hepatitis B drug targets all viral replication cycles based on coverage, which also includes the formation of cccDNA, which provides a broader combination of drug regimens for improving functional cure.